PRODUCT SPECIFICATION

[OML-SMCC) 2,5-dioxopyrroldin-1-yl (15,4)-4-([3-([5-([5-1])])) (14,4)-4-([3-([5-1])]) (14,4)-4-([3-([5-1])]) (14,4)-4-([3-([5-1])]) (14,4)-4-([3-4])) (14,4)-4-([3-4]) (14,4)





READY-MADE PAYLOADS AND LINKERS

WuXi XDC offers a growing library of common payloads and linkers for use in a variety of R&D and pharmaceutical purposes including use as chemical intermediates in the production of antibody drug conjugates (ADCs) and other bioconjugates. These ready-made and ready-to-conjugate small molecule entities can be manufactured as both GMP and non-GMP grade.

(DM1-SMCC 2,5-dioxopyrrolidin-1-yl (1S,4r)-4-((3-((3-(((S)-1-(((14S,16S,32S,33S,2R,4S,10E,12E,1-4R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-ox-azinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetra-decaphane-10,12-dien-4-yl)oxy)-1-oxopropan-2-yl) (methyl)amino)-3-oxopropyl)thio)-2,5-dioxopyrrolidin-1-yl)methyl)cyclohexane-1-carboxylate

CAS Number	1228105-51-8
Chemical Formula	C ₅₁ H ₆₆ CIN ₅ O ₁₆ S
Molecular Weight	1072.62
Quality	Non GMP / GMP
Storage Conditions	<-20 °C
Purity	>98%
DMF	Not Available
Quantity	mg to kg
Activity	Potent Microtubule Inhibitor

About WuXi XDC

WuXi XDC, a WuXi Biologics subsidiary, is a joint venture between WuXi Biologics and the WuXi AppTec subsidiary, WuXi STA. The joint venture greatly simplifies Antibody Drug Conjugate (ADC) and other bioconjugate drug development by providing all discovery, development, testing and GMP manufacturing activities for all intermediates (payloads, linkers and biologics) and the bioconjugate, under one company and in one centralized region. This co of expertise and geography greatly reduces project hand-off risks and pro-





Your Single-Source for Bioconjugation Development and cGMP Manufacturing